RU-58841 is a non-steroidal androgen receptor antagonist developed for topical application — designed specifically to block androgen receptor (AR) activation in scalp hair follicles while minimizing systemic absorption that would interfere with circulating testosterone effects. Hair follicle miniaturization in androgenetic alopecia (male pattern baldness) is driven by DHT (dihydrotestosterone) activation of AR in genetically susceptible follicles, triggering a shortening of the anagen (growth) phase and progressive miniaturization that ultimately produces vellus (unpigmented, fine) hair from terminal follicles. RU-58841 applied topically to the scalp competes with DHT for follicular AR binding, blocking the androgen signal that drives this miniaturization process without requiring systemic DHT reduction.

The mechanism distinguishes RU-58841 fundamentally from oral finasteride (5-alpha reductase inhibitor) and oral dutasteride. Finasteride reduces systemic DHT by inhibiting the enzyme that converts testosterone to DHT — but this systemic DHT reduction affects androgen signaling throughout the body, producing the well-documented side effects of sexual dysfunction, mood changes, and cognitive effects that have generated significant concern under the "Post-Finasteride Syndrome" discussion. RU-58841 targets the AR directly and only at the point of application — with sufficient topical selectivity that meaningful systemic androgenic activity is not significantly altered, preserving the systemic benefits of DHT (libido, erectile function, mood, neurotransmission) while blocking its follicular effects.

Preclinical studies in the stump-tailed macaque (a primate model of androgenetic alopecia with AR-driven hair loss matching the human phenotype) demonstrated significant hair regrowth with topical RU-58841 compared to vehicle controls — results published in peer-reviewed literature establishing the proof-of-concept for topical AR antagonism in alopecia. Clinical development was discontinued in the 1990s, not due to safety issues but due to corporate decisions at ProStrakan (the pharmaceutical developer) — the compound never progressed to Phase 3 not because of failure but because of business decisions.

The practical application of RU-58841 has driven a substantial self-experimenter community that has accumulated significant anecdotal evidence over two decades. Many users report results comparable to or better than finasteride for hair retention, without the sexual or cognitive side effects associated with systemic 5-alpha reductase inhibition. The combination with minoxidil (VEGF/potassium channel mechanism) is the most common protocol, addressing hair loss through both androgen receptor blockade (RU-58841) and follicular vasodilation and proliferation (minoxidil) — two mechanistically independent pathways to hair retention.

The 30mL bottle at standard research concentrations (25–50mg/mL in carrier vehicle) provides a 1–2 month supply at typical application doses of 50mg/day. Vehicle choice is important for delivery — the included or recommended carrier should penetrate the stratum corneum to reach follicular AR in the dermal papilla.